ArticleFolia microbiologica2025
Microbe-based fluorescent sensor composite for drug delivery and hepatocellular carcinoma suppression.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a major clinical challenge due to its late diagnosis and poor prognosis. To address these limitations, we developed a novel gefitinib derivative (DCQ-Me) and integrated it into a multifunctional fluorescent nanosystem, AL-STEROID-CHO@DCQ-ME, designed for both targeted drug delivery and real-time tumor detection. The system exhibits ratiometric fluorescence behavior, enabling sensitive detection of the HCC biomarker GP73 through a new emission signal at 500 nm and a quantifiable intensity ratio (F500/F410), with a detection limit of 0.189 mmol L⁻¹. In vitro assays further demonstrated that AL-STEROID-CHO@DCQ-ME significantly inhibits proliferation and induces apoptosis in HCC cells. These results underline the dual functionality of the platform, offering precise diagnostic readouts alongside therapeutic efficacy. Overall, this study introduces an innovative theranostic strategy with potential to improve early detection and personalized treatment of liver cancer.
Indexed as
Identifiers
41175282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.